Evidence map›Paper›PMID 38816662›Full record

ArticleJournal of endocrinological investigation2024

Mild liver dysfunction in Klinefelter syndrome is associated with abdominal obesity and elevated lipids but not testosterone treatment.

C M Øzdemir, L O Ridder, S Chang, J Fedder, J Just, C H Gravholt, A Skakkebæk

Abstract read
In one paragraph

Article in Journal of endocrinological investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

C M Øzdemir *Department of Endocrinology and Internal Medicine and Medical Research Laboratories, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark.ORCID http://orcid.org/0000-0002-5380-1288
L O Ridder *Department of Endocrinology and Internal Medicine and Medical Research Laboratories, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. lukrid@clin.au.dk.ORCID http://orcid.org/0000-0003-1110-748X
S ChangDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID http://orcid.org/0000-0003-1130-3659
J FedderCentre of Andrology and Fertility Clinic, Department D, Odense University Hospital, Odense, Denmark.ORCID http://orcid.org/0000-0001-5383-5501
J JustDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
C H GravholtDepartment of Endocrinology and Internal Medicine and Medical Research Laboratories, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark.ORCID http://orcid.org/0000-0001-5924-1720
A SkakkebækDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID http://orcid.org/0000-0001-9178-4901

Funding

Danmarks Frie Forskningsfond 0134-00130BDanmarks Frie Forskningsfond 0134-00406Novo Nordisk Fonden NNF15OC0016474Novo Nordisk Fonden NNF20OC0060610Sygesikring Danmark 2022-0189
6 · The paper itself

Abstract

contextKlinefelter syndrome (KS) is associated with hypergonadotropic hypogonadism, which contributes to characteristic phenotypical manifestations including metabolic alterations. Extensive research has demonstrated important associations between androgens and liver function.

objectivesInvestigation of the association between metabolic parameters, sex hormones and liver function in males with KS, both treated (T-KS) and untreated (U-KS) and healthy control males.

methodsA total of 65 KS males were recruited, of which 32 received testosterone replacement therapy (TRT). Also, 69 healthy controls were recruited. We used alanine aminotransferase (ALAT), alkaline phosphatase and PP (prothrombin-proconvertin time ratio) as the main liver markers. Multivariable regression was performed within the three groups. All statistics were calculated using STATA. Principal component analysis was utilized to demonstrate the interconnected patterns among all measured biomarkers, and to elucidate how the different groups were linked to these patterns.

resultsHigher levels of main liver markers were observed in U-KS compared to controls, with no significant differences between U-KS and T-KS. T-KS had lower abdominal fat, total cholesterol, and LDL cholesterol than U-KS. Using multivariable models, variation in ALAT in U-KS was explained by HOMA2%S; in T-KS by BMI and SHBG; and in controls by hip circumference and estradiol. We found no multivariable models explaining variation in PP in U-KS; in T-KS, PP was explained by BMI and LDL cholesterol, and in controls by total cholesterol. Using principal component analysis U-KS was positively associated to D1 (an obese profile, which also included ALAT) and controls negatively associated with D1 (non-obese profile).

conclusionKS males have mild liver dysfunction reflected by a significant increase in the main liver markers and decrease in albumin. The presented data underscore a primary role of metabolic conditions including obesity, insulin resistance and unfavourable lipid profile, in the elevated liver function markers seen in males with KS. Whether TRT can improve liver function in KS warrants further studies. Our findings, highlight that an evaluation of the liver function should be part of the clinical care in males with KS.

Indexed as

BiomarkersHormone Replacement TherapyKlinefelter SyndromeObesity, AbdominalTestosteroneAdultCase-Control StudiesHumansHypogonadismLipidsLiverLiver DiseasesMaleMiddle AgedBiomarkersLipidsTestosteroneCholesterolHypogonadismKlinefelter syndromeLiver dysfunctionObesityTestosterone replacement therapy

Identifiers

PMID38816662
PMCPMC11549108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.